Roger Paredes, MD, PhD
Infectiology — Hospital Universitari Germans Trias i Pujol, Spain
Roger Paredes
LeadR Profile
Infectiology
Subspecialties: Pulmonology - Public Health - Pharmacy
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1997 - 2026
Number : 495
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Blinded two-year longitudinal evaluation of SARS-CoV-2 antigenemia in long COVID. sars-cov-2, nucleocapsid, covid-19, parasitic diseases, severe acute respiratory syndrome-related coronavirus, communicable diseases, infections, plasma, post-acute covid-19 syndrome | Clin Microbiol Infect | 2026 | 1 |
| Cardiovascular Disease Risk with Integrase Inhibitor-based Antiretroviral Therapy: A Causal Inference Analysis in RESPOND. cardiovascular diseases, integrase inhibitors, therapeutics, integrases | Open Forum Infect Dis | 2026 | 0 |
| Risks of autoimmune and inflammatory post-acute COVID-19 conditions: a network cohort study in six European countries, the USA and Korea. diabetes mellitus, incidence, arthritis, cohort studies, fatigue syndrome, chronic, signs and symptoms, covid-19, sex, diagnosis, records, reinfection, diabetes mellitus, type 1, infections | BMJ Public Health | 2026 | 0 |
| Current evidence on islatravir drug resistance and implications for future HIV treatment. pharmaceutical preparations, nucleosides, rna-directed dna polymerase, hiv, therapeutics, reverse transcriptase inhibitors, mutation, antiviral agents, virus diseases, drug resistance | Top Antivir Med | 2026 | 0 |
| Andes hantavirus: operationalising science in real time. orthohantavirus | Lancet Top journal | 2026 | 0 |
Clinical Studies 34
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 36
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Safety and Effectiveness of a 10 Day Remdesivir Treatment to Prevent Severe COVID 19 in Kidney Transplant Patients with Mild or No Symptoms A Single Group Trial 2024-519272-96-00 — sars-cov-2, safety, kidney, signs and symptoms, covid-19, transplants, therapeutics, severe acute respiratory syndrome-related coronavirus, infections | Phase 2 | Recruiting | 2025 |
| DOR ISL in HIV 1 Antiretroviral Treatment na ve Participants (MK 8591A 053) NCT05705349 — hiv-1, safety, tablets, hiv, therapeutics, mouth, infections, rna | Phase 3 | Active not recruiting | 2023 |
LeadR Networks
Main global connection map